Winston - I've been invested here for a number of years. As you know, they're yet to have a trial failure across their whole portfolio. One or two of their candidates are getting towards late Phase II and Phase III trials, which should mean that an inflection point, where they move from consuming capital to generating revenue, comes sooner rather than later.
Exciting times ahead at Xenetic!